Jesús Santamaría has penned crime novels full of death — and received more than $5.8 million from the European Union toward ...

A multidrug regimen containing brentuximab vedotin (BV, Adcetris) proved feasible for older patients with advanced classical ...

Brentuximab vedotin combined with cyclophosphamide, doxorubicin, and prednisone (CHP) shows promising results as a first-line ...

Common treatment can wake up dormant cancer cells, causing the disease to spread from original sites to other organs, team ...

A team of Chinese scientists has found that the spread of cancer from original tumour sites to distant organs can be caused ...

Roche and Genentech were unable to sufficiently demonstrate the benefit of using Columvi in an earlier treatment setting for ...

U.S. inspectors have uncovered new and dangerous breakdowns in drugmaking at an Indian factory owned by Sun Pharma that ...

Researchers sought to determine whether SOC pola-R-CHP frontline therapy would be safe and effective in a real-world population of patients with treatment-naïve DLBCL.

The FDA has decided not to approve glofitamab plus gemcitabine and oxaliplatin to treat certain patients with relapsed/refractory DLBCL.

Chinese scientists have found that a common treatment wakes up dormant cancer cells, causing the deadly disease to spread from the original sites to other organs., Health, Times Now ...

Lyell Immunopharma's LYL314 CAR-T therapy shows durable responses in advanced LBCL patients. Learn about trials and upcoming ...

The FDA issued a complete response letter to Genentech indicating it cannot approve the company’s biologic license ...